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What does this study add? : Spinal application of selective serotonin 
reuptake inhibitors (SSRIs) reinstates diffuse noxious inhibitory 
controls (DNIC) acting on spinal neurons in neuropathic rats. Novel 
inhibitory actions via 5-HT7 receptors now predominate, and effects 
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observed rely on an underlying inhibitory tonic noradrenergic 
component.  
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1. Introduction 
Brainstem influences modulate spinal pain processing via descending 
pathways, whereby noradrenergic and serotonergic 
neurotransmission exerts bi-directional controls on pain perception 
(Bannister and Dickenson, 2016). Descending noradrenergic 
projections terminating in the dorsal horn of the spinal cord derive in 
particular from the locus coereleus (LC). Micro-stimulation of these 
areas is anti-nociceptive via activation of the 2-adrenoceptor (AR) 
(Jones and Gebhart 1986). Electrical stimulation of the rostral 
ventromedial medulla (RVM) evokes the spinal release of 5-
hydroxytryptamine (5-HT), whose influence on spinal cord pain 
processing is contrasting (Eide and Hole 1993); activation of spinal 
5-HT3 receptors exacerbates pain signaling (Ali et al., 1996; Green et 
al., 2000; Guo et al., 2014; Suzuki et al., 2002) but activation of 5-HT7 
receptors can be anti-nociceptive (Brenchat et al., 2010; Dogrul et al., 
2009; Dogrul and Seyrek 2006). Deciphering the role of the multiple 
5-HT receptor subtypes in nociception remains complex (Kayser et 
al., 2011). 
 
Spinal serotonergic and noradrenergic signaling is hypothesized a 
key underlying component of diffuse noxious inhibitory controls 
(DNIC) (Bannister et al., 2015; Chitour et al., 1982), a unique form of 
descending endogenous analgesia (De Broucker et al., 1990) in which 
the activity of trigeminal and wide dynamic range (WDR) neurons is 
constrained (Le Bars et al., 1979b). Originally proposed to derive 
from the subnucleus reticularis dorsalis (SRD) (Bouhassira et al., 
1992), DNIC have a complex interplay between pathways comprising 
the dorsolateral funiculus (Okada-Ogawa et al., 2009). Human brain 
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imaging studies now show that signal changes associated with the 
human counterpart of DNIC include the SRD and parabrachial 
nucleus, with the former being controlled by cortical influences 
(Youssef et al., 2016a; b).  
 
DNIC require a noxious conditioning stimulus (one pain inhibits 
another). In naïve rats, application of ear pinch activates DNIC, 
quantified as the inhibitory effect of the conditioning stimulus on 
WDR neuronal firing to hindpaw stimulation. The ear pinch was 
proposed to activate an α2 AR noradrenergic control that overrode 
excitatory serotonergic events to trigger DNIC (Bannister et al., 
2015). In spinal nerve ligated (SNL) animals there is an attenuation 
of α2 AR-mediated inhibitions and an increase in 5-HT3 receptor-
mediated nociception (Rahman et al., 2008a; Suzuki et al., 2004) 
(Dogrul et al., 2009) and DNIC were shown completely abolished. An 
important role for descending serotonergic inhibitory pathways in 
DNIC was postulated (Chitour et al., 1982). Application of the 5-HT3 
receptor antagonist ondansetron revealed DNIC in SNL animals, 
indicative of an underlying, now-dominant, 5-HT3 receptor-mediated 
facilitation restoring the normal balance in descending controls 
(Bannister et al., 2015). 
 
Following neuropathy, in addition to sustained 5-HT facilitatory 
influences on the spinal cord, the density of 5-HT7 receptors is 
increased in the dorsal horn (Brenchat et al., 2010). Given the 
complexity of serotonergic mechanisms in these spinal events, here 
we use selective serotonin reuptake inhibitors (SSRIs) to gauge the 
effect of an exaggerated spinal serotonergic content on the 
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expression of DNIC after neuropathy. We attempt to identify which 5-
HT receptor actions predominate, nociceptive or anti-nociceptive, 
and whether any effects observed rely on an underlying inhibitory 
tonic noradrenergic component.  
 
2. Methods 
2.1. Animals 
Male Sprague-Dawley rats (250-300g, Biological Services, UCL, UK) 
were used for electrophysiological experiments. Animals were group 
housed on a 12h:12h light-dark cycle. Food and water were available 
ad libitum. All procedures described were approved by the Home 
Office and adhered to the Animals (Scientific Procedures) Act 1986. 
Every effort was made to reduce animal suffering and the number of 
animals used in accordance with the IASP ethic guidelines 
(Zimmermann 1983). Total number of naïve animals used in this 
study = 16. Total number of SNL animals used in this study = 44.  
 
2.2. Spinal nerve ligation surgery 
Spinal nerve ligation (SNL) surgery was performed as described 
previously (Kim and Chung 1992). Rats (120-140g) were maintained 
under 2% v/v isoflurane anaesthesia delivered in a 3:2 ratio of 
nitrous oxide and oxygen. Under aseptic conditions, a paraspinal 
incision was made and the left tail muscle excised. Part of the L5 
transverse process was removed to expose the L5 and L6 spinal 
nerves, which were then isolated with a glass nerve hook (Ski-Ry Ltd, 
London, UK) and ligated with a non-absorbable 6-0 braided silk 
thread proximal to the formation of the sciatic nerve. The 
surrounding skin and muscle were closed with absorbable 3-0 
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sutures. All rats were monitored for normal behaviours (grooming 
and mobility) and weight gain post-surgery. 
 
2.3. Electrophysiology 
In vivo electrophysiology experiments were conducted on post-
operative days 14-18 (SNL-operated animals) or weight/age- 
matched naive rats as previously described (Urch and Dickenson 
2003). Briefly, animals were anaesthetised and maintained for the 
duration of the experiment with isofluorane (1.5%) delivered in a 
gaseous mix of N2O (66%) and O2 (33%). A laminectomy was 
performed to expose the L4-5 segments of the spinal cord. 
Extracellular recordings were made from deep dorsal horn neurons 
(lamina V-VI) using parylene coated tungsten electrodes (A-M 
systems, USA). All the neurons recorded were wide dynamic range 
(WDR) and responded to natural stimuli including brush, low and 
high intensity mechanical and thermal stimuli in a graded manner 
with coding of increasing intensity.  
The peripheral receptive field (hind paw) was stimulated using 
punctate mechanical stimuli (von Frey filaments 8, 26 and 60 g) and 
the number of action potentials fired in 5 s was recorded. Data were 
captured and analysed by a CED 1401 interface coupled to a Pentium 
computer with Spike 2 software (Cambridge Electronic Design; rate 
functions). 
Three baseline responses to mechanical stimuli as detailed above 
were characterised for each neuron before DNIC and subsequent 
pharmacological assessment (a drug study was carried out on one 
neuron per animal only).  
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2.4. DNIC study design 
Extracellular recordings were made from one WDR neuron per 
animal by stimulating the hind paw peripheral receptive field and 
then repeating in the presence of ear pinch. Ear pinch was chosen as 
the conditioning stimulus since this part of the body is distant from 
the sciatic territory where the neuropathy was performed. The 
number of action potentials fired in 5 s was recorded for each test. 
Baseline responses were calculated from the mean of 2 trials. Each 
trial consisted of 3 consecutive stable responses to 8, 26 and 60g von 
Frey filaments applied to the hind paw (where all neurons met the 
inclusion criteria of <10% variation in action potential firing for all 
mechanically-evoked neuronal responses). This was then followed by 
consecutive responses to the same mechanical stimuli (8, 26 and 60g 
von Frey filaments) in the presence of DNIC. Precisely, DNIC was 
induced using a noxious ear pinch (15.75 x 2.3 mm Bulldog Serrefine, 
Interfocus, Linton, UK) on the ear ipsilateral to the neuronal 
recording whilst concurrent to this the peripheral receptive field was 
stimulated using the von Frey filaments listed. DNIC was quantified 
as an inhibitory effect on neuronal firing during ear pinch. A one-
minute non-stimulation recovery period was allowed between each 
test in the trial. Following this, for pre-drug neuronal recordings, a 
10-minute non-stimulation recovery period was allowed before the 
entire process was repeated and data for control trial number 2 was 
collected.  
 
2.5. Drug administration 
Following collection of pre-drug baseline control data as outlined in 
section 2.4, the drugs listed below were administered (one neuron 
 8 
per animal). Each individual drug dose effect was followed for up to 
60 minutes with tests carried out at 2 time points (20 and 40 
minutes). For each time point, a trial consisted of 1) 3 consecutive 
stable responses to 8, 26 and 60g von Frey filaments (where all 
neurons met the inclusion criteria of <10% variation in action 
potential firing for all mechanically-evoked neuronal responses) 
followed by 2) consecutive responses to 8, 26 and 60g von Frey 
filaments with concurrent ear pinch. For post-drug DNIC effects, 
maximal changes from pre-drug DNIC responses are presented in the 
graphs for figures 1 -4. 
The following drugs were used: Selective serotonin reuptake 
inhibitors (SSRI’s) citalopram or fluoxetine (100μg) (Fuller et al., 
1974; Hyttel 1977; Messing et al., 1975) (Tocris UK and Sigma UK 
respectively) were dissolved in saline (50μl) and delivered alone in a 
volume of 50μl or, in some instances, delivered with α2 adrenoceptor 
antagonist atipamezole (100μg) (Rahman et al., 2008a) (Sigma UK) in 
a solution of 97% normal saline, 2% cremophor and 1% DMSO 
(50μl); 5-HT7 receptor antagonist SB269970 (100μg) (Hagan et al., 
2000) (Tocris UK) was dissolved in saline (50μl) and delivered to the 
spinal cord alone or, in some instances, in combination with 
fluoxetine or citalopram (100μg) in the same solution. For systemic 
administration of SSRI (10mg/kg for citalopram and 20mg/kg for 
fluoxetine), citalopram or fluoxetine were administered via 
subcutaneous injection. 
 
2.6. Statistical analysis 
Statistical analyses were performed using SPSSV22 (IBM, Armonk, 
NY). All data plotted in figures 1-4 are the raw firing rates, 
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representing the mean ± SEM. Statistical differences in the neuronal 
responses (raw firing rates) (dependent variable) observed following 
ear pinch (independent variable) were determined using a 2-way 
repeated measures (RM) ANOVA followed by a Bonferroni post-hoc 
test for paired compairsons. Asterisks denote statistically significant 
differences (*P<0.05, **P<0.01, ***P<0.001). 
 
3. Results 
3.1. DNIC are present in naïve rats and absent in spinal nerve ligated 
rats 
Throughout this study DNIC were induced by a noxious ear pinch 
applied to the ear ipsilateral to the neuron being recorded. The 
presence of DNIC was confirmed by a concurrent reduction in deep 
dorsal horn wide dynamic range (WDR) neuronal firing to 
stimulation of the hind paw peripheral receptive field in naïve 
animals (n = 10). This was compared to the magnitude of DNIC in 
spinal nerve ligated (SNL) (examined 14 days post-SNL surgery, n = 
22) animals. Because previously no difference in the level of neuronal 
inhibition upon activation of DNIC was observed between naïve and 
sham-operated animals (Bannister et al., 2015), naïve animals only 
were used in this study as the control group. Activation of DNIC by 
heterotopic application of an ear pinch (conditioning stimulus) 
significantly and dramatically reduced the WDR neuronal response 
to non-noxious (8g) and noxious mechanical (26 and 60g) stimuli in 
naive animal groups (2-way RM ANOVA; P < 0.001, F(1,9) = 194.42. 40, 
29 and 30% inhibition to 8, 26 and 60g vF respectively, P <0.001 for 
all forces; Bonferroni post-hoc) (Figure 1A, C). Remarkably, and as 
observed previously (Bannister et al., 2015), when the magnitude of 
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DNIC was examined in SNL rats no reduction in WDR neuronal 
response to mechanical stimuli was observed upon application of the 
conditioning stimulus (2-way RM ANOVA; P > 0.05, F(1,21) = 3.32. 10 
and 6% increase in firing rate and 0% inhibition to 8, 26 and 60g vF 
respectively. P > 0.05 for all forces Bonferonni post hoc) (Figure 1B, 
D), thereby demonstrating a complete lack of DNIC in these animals.  
The degree of inhibition was comparable (30-40%) for the three vF 
filament stimulation intensities employed in keeping with the 
original studies where the conditioning stimulus modulates both non 
noxious and noxious stimuli (Le Bars et al., 1979; Bannister et al., 
2015). 
 
3.2. DNIC are revealed in SNL rats following spinal application of the 
SSRI citalopram 
Here we investigated the effect of increasing spinal 5-HT content on 
the expression of DNIC in SNL animals. Following spinal application 
of the selective serotonin reuptake inhibitor (SSRI) citalopram 
(100μg, n = 6) the degree of inhibition produced by application of a 
noxious conditioning stimulus was dramatic and now WDR neuronal 
responses to noxious mechanical stimuli were significantly reduced  
(2-way RM ANOVA; P < 0.01, F(1,5) = 29.26. 22, 46 and 38% inhibition 
to 8, 26 and 60g vF respectively in SNL animals, P < 0.05, P < 0.01 and 
P < 0.001 respectively; Bonferroni post hoc) (Figure 2A, C). These 
data demonstrate an inhibitory effect of the elevated spinal 5-HT that 
is sufficient for DNIC to be revealed in neuropathic animals.   
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3.3. The restoration of DNIC in SNL rats following spinal application of 
citalopram is prevented by the α2 AR inhibitor atipamezole or the 5-
HT7 receptor antagonist SB269970  
Spinal application of the SSRI citalopram restored DNIC in SNL 
animals (Figure 2A, C). We aimed to identify the receptor-mediated 
action responsible for this inhibitory effect. Remarkably, in the 
presence of SB269970, a 5-HT7 receptor antagonist (Hagan et al., 
2000), spinal application of citalopram no longer reduced WDR 
neuronal responses to mechanical stimuli upon application of the 
conditioning stimulus (n = 6) (2-way RM ANOVA; P > 0.05, F(1,5) = 
0.025. 12 and 5% increase in firing rate and 0% inhibition to 8, 26 
and 60g vF respectively, P > 0.05 for all forces; Bonferroni post hoc) 
(Figure 2C, F), thereby demonstrating a complete blockade of DNIC 
and suggestive of an inhibitory action of excess spinal 5-HT via 
activation of the 5-HT7 receptor.  
There is pre-existing evidence for the involvement of noradrenaline 
function in generating DNIC (Bannister et al., 2015; Peters et al., 
2015). In order to extend these findings we examined the effect of 
dual spinal application of citalopram plus α2 AR antagonist 
atipamezole on the expression of DNIC in SNL animals. Intriguingly 
now we observed no reduction in WDR neuronal response to 
mechanical stimuli upon application of the conditioning stimulus (n = 
6) (2-way RM ANOVA; P > 0.05, F(1,5) = 0.131. 11% increase in firing 
rate, 3% inhibition and 2% increase in firing rate to 8, 26 and 60g vF 
respectively, P > 0.05 for all forces; Bonferroni post hoc) (Figure 2B, 
E). Once again a complete blockade of DNIC was demonstrated, and 
these data support the premise that an inhibitory noradrenergic tone 
must be present spinally for the expression of DNIC. 
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Of concern was a prior report relating to the possible antagonistic 
effect of SB269970 at the α2 AR (Foong and Bornstein 2009). 
Previous work has shown that spinal application of α2 AR antagonist 
atipamezole blocks the expression of DNIC in naïve rats, such that 
WDR neuronal responses are no longer inhibited during concurrent 
noxious ear pinch (Bannister et al., 2015). However in the present 
study, following topical application of SB266970 alone to the spinal 
cord of naïve rats, there was no change in baseline responses nor the 
efficacy of DNIC; WDR neuronal responses were still inhibited by 
concurrent noxious ear pinch (n = 6) (2-way RM ANOVA; P > 0.01, 
F(1,5) = 20.99. 27, 20 and 35% inhibition to 8, 8, 26 and 60g vF 
respectively, P > 0.05 and P > 0.01 respectively; Bonferroni post hoc) 
(Figure 3A). This suggests that, at this concentration and for this 
protocol at least, SB269970 is not antagonizing the α2 AR. 
Note: Spinal application of vehicle control (97% normal saline, 2% 
cremophor, 1% DMSO) had no effect on baseline neuronal firing rates 
or on the level of WDR neuronal inhibition observed upon concurrent 
ear pinch (data not shown). 
 
3.4. DNIC are revealed in SNL animals following spinal application of 
SSRI fluoxetine through 5-HT7 and α2 AR mechanisms 
In order to verify the revelatory effect of the evidently most highly 
selective SSRI citalopram (Pawlowski et al., 1985) on DNIC we 
repeated the experiments above using SSRI fluoxetine (Fuller et al., 
1991). Similarly to what we observed with spinal application of 
citalopram, in the presence of spinal fluoxetine (100μg, n = 6) there 
was a significant and dramatic reduction of WDR neuronal responses 
to noxious mechanical stimuli upon simultaneous ear pinch, which 
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achieved levels of inhibition practically identical to those observed 
following spinal application of citalopram (2-way RM ANOVA; P < 
0.001, F(1,5) = 40. 42, 38 and 34% inhibition to 8, 26 and 60g vF 
respectively in SNL animals, P < 0.05, P < 0.01 and P < 0.001 
respectively; Bonferroni post hoc) (Figure 3B). Once again, dual 
spinal application of fluoxetine and 5-HT7 receptor antagonist 
SB269970 or fluoxetine and α2 AR antagonist atipamezole resulted 
in no reduction of WDR neuronal response to mechanical stimuli 
upon application of the conditioning stimulus (n = 5 and n = 6 
respectively) (2-way RM ANOVA; P > 0.05, F(1,4) = 0.024. 7% increase 
in firing rate and 2 and 2% inhibition to 8, 26 and 60g vF 
respectively, P > 0.05 for all forces; Bonferroni post hoc; P > 0.05 for 
all forces; 2-way RM ANOVA; P > 0.05, F(1,5) = 1.33. 7, 2 and 7% 
inhibition to 8, 26 and 60g vF respectively, Bonferroni post hoc) 
(Figure 3C and D). Once more, these data demonstrate an inhibitory 
effect of the elevated spinal 5-HT that is sufficient for DNIC to be 
revealed in neuropathic animals. These results validate the effects 
observed in the presence of spinal citalopram.  
 
3.5. DNIC are not present in SNL rats following systemic application of 
citalopram or fluoxetine 
We investigated the expression of DNIC in SNL animals following 
systemic administration of citalopram (n = 4, 10mg/kg) or fluoxetine 
(n = 5, 20mg/kg). Contrasting those results observed with spinal 
application of drug, systemic administration of citalopram or 
fluoxetine resulted in no reduction of WDR neuronal response to 
mechanical stimuli upon application of the conditioning stimulus (2-
way RM ANOVA; P > 0.05, F(1,3) = 0.00022 for citalopram. 4% increase 
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in firing rate, 0 and 4% inhibition to 8, 26 and 60g vF respectively, P 
> 0.05 for all forces; Bonferroni post hoc; 2-way RM ANOVA; P > 0.05, 
F(1,4) = 0.136 for fluoxetine. 18% increase in firing rate, 6 and 4% 
inhibition to 8, 26 and 60g vF respectively, P > 0.05 for all forces; 
Bonferroni post hoc) (Figure 4A and 4B).  
 
 
Discussion 
Diffuse noxious inhibitory controls (DNIC) are a powerful 
manifestation of endogenous analgesia that describes the 
phenomena whereby application of strong pain to one part of the 
body inhibits pain in multiple remote body regions. As observed here 
and previously (Bannister et al., 2015; Le Bars et al., 1979a) the 
inhibitory action of this part-opioid descending pain modulatory 
pathway on trigeminal and wide dynamic range (WDR) neurons 
upon presentation of a conditioning stimulus is robust and reliable. 
Conditioned pain modulation (CPM), the human counterpart of DNIC, 
utilizes a clinical paradigm involving a distant painful conditioning 
stimulus used to affect a test stimulus (Yarnitsky 2010). Like DNIC 
CPM is absent in tetraplegics (Roby-Brami et al., 1987) and both are 
reduced following neuropathy to varying degrees (Bannister et al., 
2015; Niesters et al., 2014; Yarnitsky 2010). DNIC clearly involve 
noradrenergic inhibitory pathways; they are abolished by blockade 
of the α2 AR (Bannister et al., 2015; Peters et al., 2015) and after 
spinal nerve ligation (SNL), but restored by enhancing synaptic levels 
of NA. This is the case with failed CPM in patients with neuropathy, 
now a predictor of the efficacy of duloxetine, a serotonin-
noradrenaline reuptake inhibitor (SNRI) (Yarnitsky et al., 2012). 
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Further, restoration of CPM was observed following treatment with 
tapentadol, a mu opioid receptor agonist and noradrenaline reuptake 
inihibitor (MOR-NRI) (Niesters et al., 2014). This corroborates the 
animal data that noradrenaline-mediated actions at the α2 AR and 
opposing facilitations via 5-HT-mediated actions at 5-HT3 receptors 
are accountable, in part, for this change. The role of 5HT in pain 
modulation is complex due to the multiplicity of receptors. DNIC 
require inhibitory actions of 5-HT (Chitour et al., 1982) but after SNL 
are prevented from modulating spinal neuronal activity by enhanced 
5-HT3 receptor facilitations (Bannister et al., 2015). Here, the role of 
5-HT in DNIC is investigated further.  
 
We have reaffirmed unequivocally that DNIC are absent in SNL 
animals. Now we demonstrate reinstatement of DNIC in neuropathic 
animals following spinal, not systemic, application of selective 
serotonin reuptake inhibitors (SSRI’s) citalopram or fluoxetine, 
which presumably act to increase spinal 5-HT content. We provide a 
pharmacological basis for this revelatory effect since it was abolished 
completely upon joint spinal application of either SSRI with the 5-
HT7 receptor antagonist SB269970 and thus support pre-existing 
evidence of an anti-nociceptive role of 5-HT7 receptors; in chronic 
pain models descending pain inhibitory pathways from the RVM 
provoked by morphine were previously shown to rely on activation 
of spinal 5-HT7 receptors (Dogrul et al., 2009). Meanwhile the anti-
depressant tianeptine had an anti-allodynic effect in a rat model of 
neuropathy mediated via 5-HT7 receptors located on spinal 
GABAergic interneurons (Lin et al., 2015). Additionally, in a mouse 
model of neuropathy, activation of 5-HT7 receptors was shown to 
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reduce mechanical and thermal hypersensitivities, and a significant 
increase in 5-HT7 receptor densities in the dorsal horn of the spinal 
cord was shown (Brenchat et al., 2010). In contrast a pro-nociceptive 
role for the 5-HT7 receptors was previously reported in the rat 
formalin test (Rocha-Gonzalez et al., 2005). However overwhelming 
is data supporting a role of the 5-HT7 receptors in modulation of 
neuropathic pain.  
 
It is likely that the levels of 5-HT in the spinal cord and elsewhere 
determine the direction of effect of the transmitter and the particular 
receptor. Endogenous 5-HT is facilitatory (Rahman et al., 2006) and 
there is a resting 5-HT3 receptor facilitation that is enhanced after 
neuropathy and in other pain states (Bannister and Dickenson 2016; 
Dogrul and Seyrek 2006; Suzuki et al., 2002) probably due to 
increased levels of 5-HT. Yet when spinal 5-HT is elevated further by 
the SSRIs, DNIC now utilises a 5-HT7 receptor inhibitory system. 
SB269970 had no effect alone when given in the absence of elevated 
5-HT. Interestingly, the 5-HT7 receptor mediates the spinal analgesia 
produced by morphine acting through descending controls (Dogrul 
and Seyrek 2006). The facilitatory role of the 5-HT3 receptor may be 
overcome when levels of 5-HT are very high. The lack of effect of the 
SSRIs given systemically and their modest effects in patients 
compared to SNRIs likely results from their inability to raise spinal 5-
HT (or indeed NA) sufficiently. Recently citalopram reduced both 
brain activation and pain ratings in volunteers but importantly the 
effects of the drug were dependent on serotonin transporter (5-HTT) 
gene polymorphisms (Ma et al., 2016). Intriguingly the degree of CPM 
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in volunteers is compromised in the low 5-HTT expressing group 
(Lindstedt et al., 2011).  
 
Initially perplexing was the observation that the DNIC-revealing 
effect of spinal application of citalopram or fluoxetine was 
completely abolished by the α2 AR antagonist atipamezole. However 
pre-existing evidence of the involvement of noradrenaline function in 
generating DNIC remain (Bannister et al., 2015; Peters et al., 2015). 
We extend this theory by hypothesising that, even in the presence of 
a reduced noradrenergic inhibitory control via the α2 AR (as is 
understood to be the case in neuropathy), this component of 
descending modulation is nonetheless vital for the expression of 
DNIC, even in the presence of an enhanced now-inhibitory action of 
serotonin via activation of the 5-HT7 receptors. It remains unclear as 
to the mechanisms behind the spinal interactions between these 5-
HT and NA pathways but there may be cross talk or reciprocal 
controls between the two monoamines and the terminals of their 
respective descending pathways. Another conceivable substrate for 
the NA and 5HT interactions could be the spinal neurons that drive 
these systems. A population of superficial NK1 receptor expressing 
neurons is required for activation of RVM neurons, DNIC and both 
the descending α2 AR mediated-inhibitions and 5-HT3 facilitations 
(Rahman et al., 2008b; Suzuki et al., 2002). Any alteration in activity 
of these neurons produced by elevated spinal 5HT could alter the 
balance between these descending controls, exactly those we are 
studying here. 
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The SSRI’s are largely ineffective as a treatment for neuropathic pain 
(Finnerup and Attal 2015). Correspondingly when given systemically 
in SNL animals we observed no suggestive activation of DNIC. 
However, a local spinal application of citalopram or fluoxetine did 
restore DNIC. The selectivity of particular SSRI’s is a moot point, not 
least because of the reported effects on noradrenergic function. 
While fluoxetine is considered a useful tool for studying 5-HT 
neurotransmission (Fuller et al., 1991; Wong et al., 1985), questions 
regarding its selectivity have been raised following a reported effect 
on noradrenergic function (O'Flynn et al., 1991). Citalopram is 
arguably the most selective SSRI agent (Hyttel 1982; Pawlowski et al., 
1985). Here, the question of whether or not there is a noradrenergic 
component to the actions of either fluoxetine or citalopram is 
crucially relevant. Conceivably the drugs may have noradrenaline 
actions in vivo. In terms of DNIC activation in SNL animals we can be 
confident that there is a 5-HT7 receptor-mediated inhibition, but an 
adrenergic component to DNIC must exist given that blocking the α2 
AR with antagonist atipamezole in naïve animals abolishes the 
inhibitory effect on WDR neuronal responses. In SNL animals it could 
be hypothesised that there is a tonic, albeit much lower, spinal 
noradrenergic drive present that exerts inhibitory actions via the α2 
AR insufficient to allow DNIC. But now, in the presence of increased 
spinal 5-HT content as is the case following spinal application of SSRI 
(which conceivably could desensitize 5-HT3 mediated facilitations), 
this reduced noradrenergic drive is now able to generate the 
inhibitory actions of DNIC in the presence of the novel actions of 5-
HT at the inhibitory 5-HT7 receptor.  
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Is the lack of effect of systemic SSRIs in terms of restoration of DNIC 
in SNL animals due to a neural 5-HT-NA interaction? Noradrenergic 
inputs to the RVM are known to effect nociceptive modulatory 
neurons by targeting both On and Off cells (Meng et al., 1997) and a 
role for excitatory α1 AR’s and inhibitory α2 AR’s in the nucleus 
raphe magnus in opioid analgesia has been proposed (Bie et al., 
2003). Stimulation of the RVM evokes the spinal release of 5-HT. 
Likely there is cross-talk between 5-HT and NA within the midbrain 
and brainstem as well as at spinal levels. The periaqueductal grey 
(PAG) inhibits nociceptive inputs to the dorsal horn of the spinal cord 
through α2 AR (Budai et al., 1998). With systemic dosing these 
proposed supra-spinal interactions between the monoamines may be 
the basis for changes in descending systems that now do not 
culminate in inhibition of spinal nociception. Roles of the 5-HT1 
receptor as well as interactions with GABA and other transmitters 
may well also be relevant. 
 
Overall, the data reveal complex bidirectional pharmacological 
substrates for descending controls with changes in their balances 
after nerve injury and after drug treatments. The translational value 
of DNIC to CPM that can be gauged in the clinic suggests that 
monoamine modulation has promise for treating pain in patients, 
with noradrenergic mechanisms being essential whereas the effects 
of serotonin appear to depend on individual levels. The present study 
supports these approaches in patients with neuropathy, but since 
DNIC and CPM are diffuse whole body inhibitory controls these 
concepts could be extended to other patients such as those with 
fibromyalgia. 
 20 
Acknowledgements 
All persons contributing to this piece of work are listed as authors. 
 
Author Contributions 
KB contributed to conception and design of study, acquisition of data, 
analysis and interpretation of data, SNL surgeries and writing the 
manuscript, SL contributed to design of study and acquisition of data, 
LG performed SNL surgeries, RP contributed to data acquisition, AHD 
contributed to conception and design of study and finalization of 
manuscript. All authors discussed the results and commented on the 
manuscript. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21 
 
References 
Ali Z, Wu G, Kozlov A, Barasi S. The role of 5HT3 in nociceptive processing in the 
rat spinal cord: results from behavioural and electrophysiological studies. 
Neurosci Lett 1996;208: 203-207. 
Bannister K and Dickenson AH. What do monoamines do in pain modulation? 
Curr Opin Support Palliat Care 2016;10: 143-148. 
Bannister K, Patel R, Goncalves L, Townson L, Dickenson AH. Diffuse noxious 
inhibitory controls and nerve injury: restoring an imbalance between 
descending monoamine inhibitions and facilitations. Pain 2015;156: 
1803-1811. 
Bie B, Fields HL, Williams JT, Pan ZZ. Roles of alpha1- and alpha2-adrenoceptors 
in the nucleus raphe magnus in opioid analgesia and opioid abstinence-
induced hyperalgesia. J Neurosci 2003;23: 7950-7957. 
Bouhassira D, Bing Z, Le Bars D. Effects of lesions of locus 
coeruleus/subcoeruleus on diffuse noxious inhibitory controls in the rat. 
Brain Res 1992;571: 140-144. 
Brenchat A, Nadal X, Romero L, Ovalle S, Muro A, Sanchez-Arroyos R, Portillo-
Salido E, Pujol M, Montero A, Codony X, Burgueno J, Zamanillo D, Hamon 
M, Maldonado R, Vela JM. Pharmacological activation of 5-HT7 receptors 
reduces nerve injury-induced mechanical and thermal hypersensitivity. 
Pain 2010;149: 483-494. 
Budai D, Harasawa I, Fields HL. Midbrain periaqueductal gray (PAG) inhibits 
nociceptive inputs to sacral dorsal horn nociceptive neurons through 
alpha2-adrenergic receptors. J Neurophysiol 1998;80: 2244-2254. 
Chitour D, Dickenson AH, Le Bars D. Pharmacological evidence for the 
involvement of serotonergic mechanisms in diffuse noxious inhibitory 
controls (DNIC). Brain Res 1982;236: 329-337. 
De Broucker T, Cesaro P, Willer JC, Le Bars D. Diffuse noxious inhibitory controls 
in man. Involvement of the spinoreticular tract. Brain 1990;113 ( Pt 4): 
1223-1234. 
Dogrul A, Ossipov MH, Porreca F. Differential mediation of descending pain 
facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors. Brain Res 
2009;1280: 52-59. 
Dogrul A and Seyrek M. Systemic morphine produce antinociception mediated by 
spinal 5-HT7, but not 5-HT1A and 5-HT2 receptors in the spinal cord. Br J 
Pharmacol 2006;149: 498-505. 
Eide PK and Hole K. The role of 5-hydroxytryptamine (5-HT) receptor subtypes 
and plasticity in the 5-HT systems in the regulation of nociceptive 
sensitivity. Cephalalgia 1993;13: 75-85. 
Finnerup NB and Attal N. Pharmacotherapy of neuropathic pain: time to rewrite 
the rulebook? Pain management 2015. 
Foong JP and Bornstein JC. 5-HT antagonists NAN-190 and SB 269970 block 
alpha2-adrenoceptors in the guinea pig. Neuroreport 2009;20: 325-330. 
Fuller RW, Perry KW, Molloy BB. Effect of an uptake inhibitor on serotonin 
metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N-
methyl-3-phenylpropylamine (Lilly 110140). Life sciences 1974;15: 
1161-1171. 
 22 
Fuller RW, Wong DT, Robertson DW. Fluoxetine, a selective inhibitor of 
serotonin uptake. Med Res Rev 1991;11: 17-34. 
Green GM, Scarth J, Dickenson A. An excitatory role for 5-HT in spinal 
inflammatory nociceptive transmission; state-dependent actions via 
dorsal horn 5-HT(3) receptors in the anaesthetized rat. Pain 2000;89: 81-
88. 
Guo W, Miyoshi K, Dubner R, Gu M, Li M, Liu J, Yang J, Zou S, Ren K, Noguchi K, 
Wei F. Spinal 5-HT3 receptors mediate descending facilitation and 
contribute to behavioral hypersensitivity via a reciprocal neuron-glial 
signaling cascade. Mol Pain 2014;10: 35. 
Hagan JJ, Price GW, Jeffrey P, Deeks NJ, Stean T, Piper D, Smith MI, Upton N, 
Medhurst AD, Middlemiss DN, Riley GJ, Lovell PJ, Bromidge SM, Thomas 
DR. Characterization of SB-269970-A, a selective 5-HT(7) receptor 
antagonist. Br J Pharmacol 2000;130: 539-548. 
Hyttel J. Neurochemical characterization of a new potent and selective serotonin 
uptake inhibitor: Lu 10-171. Psychopharmacology (Berl) 1977;51: 225-
233. 
Hyttel J. Citalopram--pharmacological profile of a specific serotonin uptake 
inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol 
Psychiatry 1982;6: 277-295. 
Jones SL and Gebhart GF. Characterization of coeruleospinal inhibition of the 
nociceptive tail-flick reflex in the rat: mediation by spinal alpha 2-
adrenoceptors. Brain Res 1986;364: 315-330. 
Kayser V, Latremoliere A, Hamon M, Bourgoin S. N-methyl-D-aspartate receptor-
mediated modulations of the anti-allodynic effects of 5-HT1B/1D receptor 
stimulation in a rat model of trigeminal neuropathic pain. Eur J Pain 
2011;15: 451-458. 
Kim SH and Chung JM. An experimental model for peripheral neuropathy 
produced by segmental spinal nerve ligation in the rat. Pain 1992;50: 
355-363. 
Le Bars D, Dickenson AH, Besson JM. Diffuse noxious inhibitory controls (DNIC). 
I. Effects on dorsal horn convergent neurones in the rat. Pain 1979a;6: 
283-304. 
Le Bars D, Dickenson AH, Besson JM. Diffuse noxious inhibitory controls (DNIC). 
II. Lack of effect on non-convergent neurones, supraspinal involvement 
and theoretical implications. Pain 1979b;6: 305-327. 
Lin H, Heo BH, Kim WM, Kim YC, Yoon MH. Antiallodynic effect of tianeptine via 
modulation of the 5-HT7 receptor of GABAergic interneurons in the spinal 
cord of neuropathic rats. Neurosci Lett 2015;598: 91-95. 
Lindstedt F, Berrebi J, Greayer E, Lonsdorf TB, Schalling M, Ingvar M, Kosek E. 
Conditioned pain modulation is associated with common polymorphisms 
in the serotonin transporter gene. PloS one 2011;6: e18252. 
Ma Y, Wang C, Luo S, Li B, Wager TD, Zhang W, Rao Y, Han S. Serotonin 
transporter polymorphism alters citalopram effects on human pain 
responses to physical pain. Neuroimage 2016;135: 186-196. 
Meng XW, Budra B, Skinner K, Ohara PT, Fields HL. Noradrenergic input to 
nociceptive modulatory neurons in the rat rostral ventromedial medulla. 
The Journal of comparative neurology 1997;377: 381-391. 
 23 
Messing RB, Phebus L, Fisher LA, Lytle LD. Analgesic effect of fluoxetine 
hydrochloride (Lilly 110140), a specific inhibitor of serotonin uptake. 
Psychopharmacol Commun 1975;1: 511-521. 
Niesters M, Proto PL, Aarts L, Sarton EY, Drewes AM, Dahan A. Tapentadol 
potentiates descending pain inhibition in chronic pain patients with 
diabetic polyneuropathy. Br J Anaesth 2014;113: 148-156. 
O'Flynn K, O'Keane V, Lucey JV, Dinan TG. Effect of fluoxetine on noradrenergic 
mediated growth hormone release: a double blind, placebo-controlled 
study. Biol Psychiatry 1991;30: 377-382. 
Okada-Ogawa A, Porreca F, Meng ID. Sustained morphine-induced sensitization 
and loss of diffuse noxious inhibitory controls in dura-sensitive medullary 
dorsal horn neurons. J Neurosci 2009;29: 15828-15835. 
Pawlowski L, Nowak G, Gorka Z, Mazela H. Ro 11-2465 (cyan-imipramine), 
citalopram and their N-desmethyl metabolites: effects on the uptake of 5-
hydroxytryptamine and noradrenaline in vivo and related 
pharmacological activities. Psychopharmacology (Berl) 1985;86: 156-
163. 
Peters CM, Hayashida K, Suto T, Houle TT, Aschenbrenner CA, Martin TJ, 
Eisenach JC. Individual differences in acute pain-induced endogenous 
analgesia predict time to resolution of postoperative pain in the rat. 
Anesthesiology 2015;122: 895-907. 
Rahman W, D'Mello R, Dickenson AH. Peripheral nerve injury-induced changes in 
spinal alpha(2)-adrenoceptor-mediated modulation of mechanically 
evoked dorsal horn neuronal responses. J Pain 2008a;9: 350-359. 
Rahman W, Suzuki R, Hunt SP, Dickenson AH. Selective ablation of dorsal horn 
NK1 expressing cells reveals a modulation of spinal alpha2-adrenergic 
inhibition of dorsal horn neurones. Neuropharmacology 2008b;54: 1208-
1214. 
Rahman W, Suzuki R, Webber M, Hunt SP, Dickenson AH. Depletion of 
endogenous spinal 5-HT attenuates the behavioural hypersensitivity to 
mechanical and cooling stimuli induced by spinal nerve ligation. Pain 
2006;123: 264-274. 
Roby-Brami A, Bussel B, Willer JC, Le Bars D. An electrophysiological 
investigation into the pain-relieving effects of heterotopic nociceptive 
stimuli. Probable involvement of a supraspinal loop. Brain 1987;110 ( Pt 
6): 1497-1508. 
Rocha-Gonzalez HI, Meneses A, Carlton SM, Granados-Soto V. Pronociceptive role 
of peripheral and spinal 5-HT7 receptors in the formalin test. Pain 
2005;117: 182-192. 
Suzuki R, Morcuende S, Webber M, Hunt SP, Dickenson AH. Superficial NK1-
expressing neurons control spinal excitability through activation of 
descending pathways. Nature neuroscience 2002;5: 1319-1326. 
Suzuki R, Rahman W, Hunt SP, Dickenson AH. Descending facilitatory control of 
mechanically evoked responses is enhanced in deep dorsal horn neurones 
following peripheral nerve injury. Brain research 2004;1019: 68-76. 
Urch CE and Dickenson AH. In vivo single unit extracellular recordings from 
spinal cord neurones of rats. Brain research Brain research protocols 
2003;12: 26-34. 
 24 
Wong DT, Reid LR, Bymaster FP, Threlkeld PG. Chronic effects of fluoxetine, a 
selective inhibitor of serotonin uptake, on neurotransmitter receptors. J 
Neural Transm 1985;64: 251-269. 
Yarnitsky D. Conditioned pain modulation (the diffuse noxious inhibitory 
control-like effect): its relevance for acute and chronic pain states. 
Current opinion in anaesthesiology 2010;23: 611-615. 
Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. 
Conditioned pain modulation predicts duloxetine efficacy in painful 
diabetic neuropathy. Pain 2012;153: 1193-1198. 
Youssef AM, Macefield VG, Henderson LA. Cortical influences on brainstem 
circuitry responsible for conditioned pain modulation in humans. Hum 
Brain Mapp 2016a;37: 2630-2644. 
Youssef AM, Macefield VG, Henderson LA. Pain inhibits pain; human brainstem 
mechanisms. Neuroimage 2016b;124: 54-62. 
Zimmermann M. Ethical guidelines for investigations of experimental pain in 
conscious animals. Pain 1983;16: 109-110. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 25 
 
Figure Legends 
Figure 1 
The effect of DNIC activation on response profiles of deep dorsal horn 
WDR neurons in naïve (n = 10) and spinal nerve ligated (SNL) (n = 
22) rats is shown. All data are presented as the mean ± standard 
error of the mean. Here, the DNIC effect is expressed as the maximal 
evoked change in neuronal response. In all experimental groups the 
evoked responses to mechanical stimuli were recorded before and 
after activation of DNIC. A noxious ear pinch ipsilateral to the 
neuronal receptive field significantly reduced the excitability of 
spinal neurons to simultaneous peripherally applied non-noxious 
and noxious stimuli in naïve animals (A). A noxious ear pinch 
ipsilateral to the neuronal receptive field had no statistically 
significant effect on the excitability of spinal neurons to peripherally 
applied stimuli in SNL rats (B). The first representative trace shows 3 
control responses to von Frey filaments and a response profile 
following the simultaneous application of a noxious ear pinch. There 
is a statistically significant comparative reduction in neuronal action 
potential firing following activation of DNIC in naïve animals (C). 
There is no statistically significant reduction in neuronal action 
potential firing following activation of DNIC in SNL rats on the 
ipsilateral side (D). Traces represent single unit recordings. Columns 
represent number of spikes per second. Significant differences from 
baseline response: *P < 0.05, **P < 0.01, ***P < 0.001. 
 
Figure 2 
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The effect of 1) spinal citalopram (100ug) and 2) spinal citalopram 
plus atipamezole (100ug) and 3) spinal citalopram plus SB269970 
(100ug) on the response profiles of deep dorsal horn WDR neurons 
in SNL animals (n = 6 for all groups) is shown. All data are presented 
as the mean ± standard error of the mean. Here the DNIC effect is 
expressed as the maximal evoked change in neuronal response. In all 
experimental groups the evoked responses to mechanical stimuli 
were recorded before and after activation of DNIC. In the presence of 
spinal citalopram following a noxious ear pinch the excitability of 
spinal neurons to simultaneous peripherally applied mechanical 
stimuli was significantly reduced (A). However when citalopram was 
applied in the presence of spinal atipamezole or SB-269970, noxious 
ear pinch now had no statistically significant effect on the excitability 
of spinal neurons to simultaneous peripherally applied non-noxious 
and noxious stimuli (B and C). The three representative traces each 
show one example of a pre-drug control and then the response 
profile following the simultaneous application of a noxious ear pinch, 
and then one example of a post-drug control and the response profile 
following the simultaneous application of a noxious ear pinch (D, E 
and F). Traces represent single unit recordings. Columns represent 
number of spikes per second. Significant differences from baseline 
response: *P < 0.05, **P < 0.01, ***P < 0.001. 
 
Figure 3 
The effect of 1) spinal SB269970 (100ug) (n = 6) on the response 
profiles of deep dorsal horn WDR neurons in naive animals and 2) 
spinal fluoxetine (100ug) (n = 6), 3) spinal fluoxetine plus 
atipamezole (100ug) (n = 6), 4) spinal fluoxetine plus SB269970 
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(100ug) (n = 5) on the response profiles of deep dorsal horn WDR 
neurons in SNL animals, is shown. All data are presented as the mean 
± standard error of the mean. Here the DNIC effect is expressed as 
the maximal evoked change in neuronal response. In all experimental 
groups the evoked responses to mechanical stimuli were recorded 
before and after activation of DNIC. In naïve animals following a 
noxious ear pinch the excitability of spinal neurons to simultaneous 
peripherally applied mechanical stimuli was significantly reduced in 
the presence of spinal SB269970 (A). In the presence of spinal 
fluoxetine following a noxious ear pinch the excitability of spinal 
neurons to simultaneous peripherally applied mechanical stimuli 
was significantly reduced in SNL animals (B). However in SNL 
animals when fluoxetine was applied in the presence of spinal 
atipamezole or SB269970, noxious ear pinch now had no statistically 
significant effect on the excitability of spinal neurons to simultaneous 
peripherally applied non-noxious and noxious stimuli (C and D). 
Significant differences from baseline response: *P < 0.05, **P < 0.01. 
 
Figure 4 
The effect of systemic citalopram (n = 5) and systemic fluoxetine (n = 
6) (10mg/kg and 20mg/kg respectively) on the response profiles of 
deep dorsal horn WDR neurons in SNL animals is shown. All data are 
presented as the mean ± standard error of the mean. Here the DNIC 
effect is expressed as the maximal evoked change in neuronal 
response. In all experimental groups the evoked responses to 
mechanical stimuli were recorded before and after activation of 
DNIC. In the presence of systemic citalopram or systemic fluoxetine 
there was no reduction in excitability of spinal neurons to 
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simultaneous peripherally applied mechanical stimuli in the 
presence of noxious ear pinch (A and B).  
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